Occoris - Self Activating Smart Inhaler

Occoris - 自激活智能吸入器

• 批准号: EP/N510087/1
• 负责人: Darragh Murnane
• 金额: $ 17.68万
• 依托单位: University of Hertfordshire
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FN510087%2F1
• 关键词: Occoris; Self; Activating; Smart; Inhaler

The ability to target lung deposition to the diseased airways is influenced by the patient's cognitive ability to handle thedevice correctly, his/her inspiratory profile, and the mechanism of aerosolization of the inhaler. This project focuses on thedevelopment of a novel aerosol generation device called Occoris. Unlike conventional pMDIs, Occoris has no need forpropellants and is recyclable. Similar to DPIs, the aerosol is generated on-demand by the patient. However, because thedrug formulation is pre-packaged in pressurized blisters, the aerosolization is self-activating and is not driven by a forcefulinhalation. When the patient inhales, the blister ruptures, and releases a fine aerosol of drug suitable for deep lunginhalation. Occoris therefore has potential for:1. Coordination of drug delivery with inhalation;2. Minimized throat deposition, compared to pMDIs (even breath-actuated pMDIs);3. Minimized pulmonary function-derived variability of lung deposition between patients;4. Consistency of aerosol dose and properties for high-dose DPI products.In this research programme, we will seek to develop a mechanism to target drug aerosols to diseased regions of the lungthrough controlling patient's inspiratory flow rate and the release rate of aerosol particles during an inhalation cycle. Thisunique achievement for DPI drug delivery derives from the novel aerosolization mechanism of the Occoris blister design.Aerosol generation will be studied using a human inhalation simulator to reproduce inhalation profiles recorded from OLDpatients. Drug formulations will be engineered to achieve high dispersibility in studies supported by the development ofadvanced analytical methods that test for chemical stability and compatibility with Occoris components. Blister packingcomponents will be engineered using air-permeable fibre meshes to support the formulations within aluminium blisters thatare designed to rupture when a patient inhales. The knowledge gained from these studies will be translated into productsthat minimize throat deposition and maximize deep lung targeting of therapeutic aerosols for the treatment of lungdiseases.

将肺部沉积物靶向病变气道的能力受到患者正确操作器械的认知能力、他/她的吸气曲线和吸入器雾化机制的影响。本项目的重点是开发一种新型气溶胶发生装置Occoris。与传统的pMDI不同，Occoris不需要推进剂，并且可以回收利用。与DPI类似，气雾剂由患者按需生成。然而，由于药物制剂是预先包装在加压泡罩中，雾化是自激活的，而不是由强力吸入驱动的。当病人吸气时，水泡破裂，并释放出一种适于深呼吸的药物气雾剂。因此，Occoris具有以下潜力：1。药物递送与吸入的协调;2.与pMDI（甚至呼吸驱动的pMDI）相比，最小化喉部沉积;3.最小化患者之间肺沉积的肺功能衍生的变异性;4.高剂量DPI产品的气雾剂剂量和性质的一致性在这项研究计划中，我们将寻求开发一种机制，通过控制患者在吸入周期中的吸气流量和气雾剂颗粒的释放速率，将药物气雾剂靶向肺部病变区域。DPI给药的这一独特成就源于Occoris泡罩设计的新颖雾化机制。将使用人体吸入模拟器研究气雾剂的产生，以重现从OLD患者记录的吸入曲线。通过开发先进的分析方法，测试化学稳定性和与Occoris成分的相容性，药物配方将被设计成在研究中实现高稳定性。泡罩包装组件将采用透气纤维网设计，以支持铝泡罩内的配方，这些铝泡罩设计为在患者吸入时破裂。从这些研究中获得的知识将转化为产品，最大限度地减少咽喉沉积和最大限度地提高治疗性气雾剂的肺部深部靶向治疗肺部疾病。